Lumora appoints Industry Veteran, Jim Reid, as Chairman as Company gears up for major commercial push

Lumora appoints Industry Veteran, Jim Reid, as Chairman as Company gears up for major commercial push

 

Cambridge, UK, Monday 11 February 2013 ... Lumora, a provider of state-of-the-art molecular diagnostic products into both the clinical and industrial markets, has appointed Jim Reid as Chairman.

 

Jim brings a wealth of experience to the board at Lumora, having spent over 35 years in the bioscience and diagnostic industries in a number of positions across Europe, with Organon, Bioscot, Roche, Chiron and Trinity Biotech. He also holds a number of non-executive director positions including Sistemic Ltd., Ocutec Ltd., and BioFilm Ltd. He has been involved in the molecular diagnostic industry since the late 1980s and was responsible for the first introduction of molecular diagnostic tests to the UK in 1991 while at Roche. Jim has also successfully developed a number of molecular diagnostic companies and has successful exits from some of these including the sale of Qnostics to BBI plc (now Alere).

 

Laurence Tisi, CEO of Lumora said: “Jim’s appointment comes at an important time for the business during a phase of significant growth and opportunity. Having significantly strengthened the management team, and with Jim’s appointment as Chairman, Lumora is now well placed to fulfil its ambitions and become a significant force in the global molecular diagnostics market.”

 

Jim Reid added: “Lumora has developed some excellent technologies which could be transformational for the molecular diagnostic industry. The molecular diagnostic sector is the fastest growing sector of the diagnostic market and Lumora is well placed to offer partners a significant step-change in crucial areas which have proved difficult or impossible to address with existing technologies. The potential to move molecular testing close to the patient, without the need for sophisticated laboratories or expensive equipment, means that the industry can deliver the promise of true near patient testing.”

 

For further information please contact:

Tony Stephenson, PR Consultant

Tel: +44 (0)7899 796655

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Download PDF here

 

Notes to Editors:

Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non clinical or industrial markets. Lumora’s easy to deploy and use technology can be employed in fields as diverse as food safety testing, and medical diagnostics. The Company is very active in licensing its technology and development partners include international biotechnology, clinical diagnostic and industrial microbiology companies.

 

Lumora’s corporate office is based just outside of Cambridge, England. The Company's investors include; Cambridge Enterprise, (University of Cambridge) Tate Lyle Ventures LP, and Catapult Venture Managers Ltd.

News

Together We believe that molecular diagnostics doesn’t need to be costly or difficult to perform.
Industrial
Discovery Our mission is to make nucleic acid detection more widely available through the development of robust, easy-to-use and affordable testing systems.
A work flow based approach using proprietary technology to simplify clinical Mdx.
Clinical
Detection Together we are taking molecular diagnostics to places that current systems haven’t been able to reach
Novel technologies in Sample prep, amplification and detection.
Technology
Sample prep & Technology
Applying novel molecular diagnostic solutions to industrial microbiology.
Clinical